Short answer
Nurix Therapeutics, Inc. (NRIX) filed its Q3 2026 10-Q quarterly report on Oct 13, 2026 for the quarter ended Aug 31, 2026. Quarterly revenue was $673M (up 8426.3% year over year) with net income of $550M.
Q3 2026 key financials · XBRL
- Revenue
- $673M
- +8426.3% YoY · +7342.9% QoQ
- Net income
- $550M
- +736.2% YoY · +714.1% QoQ
- Operating margin
- 83.1%
- EPS (diluted)
- $4.86
- +571.8% YoY · +700.0% QoQ
Source: XBRL data from the Nurix Therapeutics, Inc. (NRIX) Q3 2026 10-Q on SEC EDGAR. USD.
Nurix Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $673.1M, up $665.2M YoY, driven by $653.2M Roche license revenue
- Net income $549.8M vs $86.4M loss YoY, operating margin 83.1% vs negative 1,157.6%
- Roche collaboration best contributor: $653.2M license revenue, versus Pfizer collaboration revenue $9.7M
- Operating cash flow $447.1M vs $181.6M use YoY, cash and securities $1.1B
- Near-term funding sufficient for at least 12 months, with substantial additional capital required long term
Risk Factors
- Newly added commercialization risk: Roche collaboration triggered transition to commercial operations, requiring new sales, compliance and market-access capabilities
- Most materially updated clinical risk: Phase 3 DAYBreak CLL-306 enrolled its first patient in August 2026, expanding exposure to late-stage safety findings
- Regulatory risk: Loper Bright increased litigation and judicial scrutiny of FDA, CMS and HHS interpretations, potentially affecting future pricing and reimbursement
- Competitive risk: Multiple BTK degrader programs now in clinical development, increasing pressure on bexobrutideg’s market opportunity
- Liquidity risk: $1.1 billion in cash, equivalents and marketable securities supports operations through at least the next 12 months, but additional funding remains necessary long term
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nurix Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.